1 / 13

Hormonal Contraceptives – Considerations for Women with HIV and AIDS

Hormonal Contraceptives – Considerations for Women with HIV and AIDS. Hormonal Contraceptives. Combined oral contraceptive pills (COCs) Progestin-only oral contraceptive pills (POPs) Injectables (Depo-Provera/DMPA) Implants (Norplant, Jadelle, Sinoplant, Implanon).

zuzela
Download Presentation

Hormonal Contraceptives – Considerations for Women with HIV and AIDS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hormonal Contraceptives – Considerations for Women with HIV and AIDS

  2. Hormonal Contraceptives • Combined oral contraceptive pills (COCs) • Progestin-only oral contraceptive pills (POPs) • Injectables (Depo-Provera/DMPA) • Implants (Norplant, Jadelle, Sinoplant, Implanon)

  3. Hormonal Contraceptive Methods: Appropriate for Women with HIV • Very effective • Easy to use • Suitable for short- or long-term use • Reversible • Non-contraceptive health benefits • Serious complications extremely rare

  4. ? ? ? ? ? 4 Overview:Theoretical Concerns about Hormonal Methods For women with HIV: • ARVs may reduce method effectiveness or increase side effects • Contraceptives may affect ARV efficacy • Hormonal methods may possibly affect • infectivity • disease progression Future research may lead to changes in clinical practices. Source: Leitz, 2000; Piscitelli, 1996.

  5. How ARVs Interact with COCs • May cause an increase or decrease of hormone levels • Some ARVs speed up liver metabolism and could lower blood levels of contraceptive hormones, may reduce method effectiveness • Not all ARV classes interact with contraceptive hormones (e.g., NRTIs)

  6. Source: WHO, 2004; Ouellet, 1998. Interactions between COCs and PIs

  7. Interactions between COCs and NNRTIs teratogen No significant interaction was found between ARV drugs and progestin-only injectables particularly DMPA. Source: WHO, 2004; Cohn, 2005.

  8. ? ? ? ? ? 4 Clinical Significance of COC/ARV Interaction Is Unknown • Studies examining clinical outcomes are needed (i.e., pregnancy rates, ovulation indicators) • No data on interaction between ARVs and hormonal contraceptives other than COCs and DMPA • Ritonavir-boosted protease inhibitors reduce contraceptive hormone blood levels considerably • not generally recommended for women on oral contraceptives or combined injectables • not part of first-line ARV regimens

  9. Hormonal Contraceptive Use:Increases Risk of Cervical Infection * not statistically significant when adjusted for demographic factors Source: Lavreys, 2004.

  10. ? ? ? ? ? 4 Hormonal Contraceptive Use: May Increase HIV Shedding • HIV shedding may increase risk of HIV transmission to partner • In one study, modest increase in cervical shedding of HIV-infected cells but no free virus • Impact on infectivity is uncertain Source: Wang, 1999; Wang, 2004; John, 2001.

  11. More HIV virus may increase risk of transmis-sion to partner Cervical STI infections may also increase cervical shedding of HIV Using hormonal contraceptives may increase: • risk of acquiring cervical STIs • cervical shedding of HIV ? ? ? ? ? 4 Relationships Require Further Research Future research may lead to changes in clinical practices. Source: McClelland, 2001; Ghys, 1997.

  12. ? ? ? ? ? 4 Hormonal Contraceptive Use:Theoretically May Affect Disease Progression Use of hormonal contraceptives near the time of HIV acquisition is associated with: • Higher viral load set point (indicator of disease progression) • Infection with multiple subtypes of HIV, resulting in faster CD4 decline Future research may lead to changes in clinical practices. Viral load increases after initial infection Immune system’s killer cells respond Viral load is reducedHigher set point Lower set point Source: Lavreys, 2004; Sagar, 2003.

  13. Hormonal Contraceptive Use and HIV: What Providers Should Do • Counsel clients that certain ARV drugs reduce blood levels of contraceptive hormones which in theory may reduce method effectiveness (except DMPA) • Encourage clients to tell providers which drugs they are taking • When there is a choice, prescribe ARV drugs that do not interact with hormonal methods • Encourage correct and consistent use of contraceptive method • Keep abreast of guidelineupdates

More Related